-
Results for the Second Quarter 2018
Sales for the first half of 2018 increased by 4,7 % and ended at MNOK 150,4 (MNOK 143,5). Currency neutral growth of own products was 19,3 % for the second quarter. Operating profit (EBIT) ended…
Read more -
REQUEST Interim Results: Significant Impact on Surgical Strategy with Medistim’s Devices
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and transit time flow measurement (TTFM) performed with Medistim’s VeriQ C or MiraQ devices will change the…
Read more -
Results for the First Quarter 2018
Currency neutral sales of own products decreased with 2.7 %. Operating profit (EBIT) ended at MNOK 13.6 (MNOK 16.0). Medistims equipment received an updated recommendation by NICE in UK. Data collection in the REQUEST study…
Read more -
Annual Report 2017
We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 20% measured as the share of bypass procedures…
Read more -
Renewed NICE recommendation for adopting Medistim technology in the NHS
Approximately 17,000 isolated coronary artery bypass graft (CABG) operations are performed in the UK each year. In addition, a substantial proportion of patients having other cardiac surgery have concomitant CABG. The National Institute for Health…
Read more -
Medistim REQUEST Multicenter Registry Study Results to be Presented at AATS in April
The objective for the REQUEST study is to document how often the combination of high-resolution ultrasound imaging and transit time flow measurements (TTFM) performed with Medistim's VeriQC or MiraQ devices will change the surgical procedure.…
Read more -
Results for the Fourth Quarter and Preliminary Results for 2017
Currency neutral sales of own products increased by 31.3 % for the quarter. For 2017, currency neutral growth in sales of own products was 15.7%. EBIT for the quarter ended at MNOK 16.4 (MNOK 9.7),…
Read more -
Medistim joins GE Vingmed Ultrasound and Sensocure in the development of new production technology
Sensocure, GE Vingmed Ultrasound and Medistim have been granted funding of MNOK 14,4 over 3 years from the BIA Health program at the Norwegian Research Council, for the project «Advanced Manufacturing Technologies for High Impact…
Read more -
Results for the Third Quarter 2017
Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…
Read more -
Results for the Second Quarter 2017
Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.